Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 Days Inventory is 172.20 as of Mar. 2026, which is 3% below its 10-year median of 176.89. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Corona Remedies ranks worse than 73.02% on this metric.
The historical rank and industry rank for Corona Remedies's Days Inventory or its related term are showing as below:
NSE:CORONA'
s Days Inventory Range Over the Past 10 Years
Min: 163.93 Med: 176.89 Max: 236.36
Current: 236.36
During the past 4 years, Corona Remedies's highest Days Inventory was 236.36. The lowest was 163.93. And the median was 176.89.
NSE:CORONA's Days Inventory is ranked worse than 73.02% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs NSE:CORONA: 236.36
Corona Remedies's Days Inventory
increased
from Dec. 2024 (162.57) to Mar. 2026 (172.20).
It might indicate that Corona Remedies's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Corona Remedies's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.53.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Corona Remedies's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.35.
Corona Remedies (NSE:CORONA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Corona Remedies's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Corona Remedies's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Corona Remedies Days Inventory Related Terms
Corona Remedies Days Inventory Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a Days Inventory of 172.20 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Corona Remedies and its competitors. This is near median its historical median of 176.89. Over the past decade, Corona Remedies' Days Inventory has ranged from 163.93 to 236.36. According to the industry distribution chart, Corona Remedies ranks #674 out of 923 companies in the Drug Manufacturers industry, placing it in the top 73%.
Is Corona Remedies' Days Inventory too high?
Corona Remedies' current Days Inventory of 172.20 is near median its 10-year median of 176.89. Over the past 10 years, this metric has ranged from a low of 163.93 to a high of 236.36. The Drug Manufacturers industry median Days Inventory is 164.87. Corona Remedies' value of 172.20 is 4.4% above this industry median. Based on the distribution chart, Corona Remedies ranks #674 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #674 out of 923 companies for Days Inventory. This places Corona Remedies in the lower half of its industry. The industry median Days Inventory is 164.87. Corona Remedies' value of 172.20 is 4.4% above this benchmark. Historically, Corona Remedies' own Days Inventory has ranged from 163.93 to 236.36 over the past decade. While the company's 10-year median is 176.89 vs. the industry median of 164.87, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Days Inventory of 172.20 is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Days Inventory is 172.20, which is near median its own 10-year median of 176.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Days Inventory of 172.20. The current Days Inventory is 172.20, which is near median its 10-year median of 176.89 and 4.4% above the Drug Manufacturers industry median of 164.87. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Days Inventory is 172.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
